GlassScriptPhysician profile
Jason T Hedrick
NPI 1417161753
$3,920.60
in general payments reported to CMS, 2019-2025
21 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 76% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $772 · 2021: $165 · 2022: $170 · 2023: $504 · 2024: $733 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $1,452.55 | 2019-2025 | |
| Mentor Worldwide LLC | $681.77 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Kerecis Limited | $574.12 | 2023-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Surgiclose |
| Integra Lifesciences Corporation | $399.54 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Solventum Corporation | $230.41 | 2024-2025 | Prevena Restor Bellaform, V.A.C. Veraflo, V.A.C.Ulta |
| Convatec INC. | $100.90 | 2025 | |
| Allergan, INC. | $86.08 | 2019-2021 | |
| Axogen | $61.28 | 2022-2025 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Becton, Dickinson and Company | $56.75 | 2025 | Phasix Mesh |
| Kci USA, INC. | $39.86 | 2020-2023 | Prevena Restor Bellaform, Spoton, V.A.C. Veraflo Cleanse Choice |
| Sientra, INC. | $33.83 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $30.10 | 2021-2022 | |
| Heron Therapeutics, INC. | $28.75 | 2022 | |
| Avanos Medical | $24.51 | 2023 | On-Q* Pump and Accessories |
| Davol INC. | $24.21 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.22 | 2022 | |
| Abbvie INC. | $18.67 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $15.12 | 2024 | Exparel |
| Tepha INC | $14.80 | 2019 | |
| Elutia, INC. | $14.47 | 2021 | |
| Merz North America, INC. | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hedrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.